By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galapagos NV 

Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen    B-2800  Belgium
Phone: 32-15-34-29-00 Fax: 32-15-34-29-01



Company News
Galapagos (GLPG.BR) Release: Publication Of The Annual Report And Invitation To The Annual And Extraordinary Shareholders' Meetings 3/24/2017 8:00:08 AM
Galapagos (GLPG.BR) Release: New Phase II Studies With Filgotinib In Small Bowel And Fistulizing Crohn's Disease 3/10/2017 7:35:50 AM
PHARNEXT Announces R&D Agreement With Galapagos (GLPG.BR) To Generate A New Pipeline Of Synergistic Drug Combinations 3/9/2017 10:03:06 AM
Galapagos (GLPG.BR) Doses First Healthy Volunteer With CF Combo GLPG2222 And GLPG2451 2/24/2017 7:30:32 AM
Galapagos (GLPG.BR) Reports Strong Financial Results And Newsflow-Rich Pipeline 2/24/2017 7:27:20 AM
Galapagos (GLPG.BR) Doses First Patient With Novel CF Corrector GLPG2222 2/2/2017 7:47:16 AM
Galapagos (GLPG.BR) Release: Dr. Walid Abi-Saab Joins Company As Chief Medical Officer 1/18/2017 12:41:14 PM
Galapagos (GLPG.BR)'s SAPHIRA 1 Topline Shows Competitive Clinical Results In G551D Patients 12/21/2016 9:44:21 AM
Galapagos (GLPG.BR) Release: The Lancet Publishes FITZROY Study Results With Filgotinib In Crohn's 12/15/2016 10:21:25 AM
Galapagos (GLPG.BR) Release: Start Phase 2b/3 Study With Filgotinib In Ulcerative Colitis 12/9/2016 9:46:28 AM